You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Gene therapy company launched

Fidelity Biosciences, a venture capital firm that is a subsidiary of Fidelity Investments, and REGENX Biosciences, announced the formation of Dimension Therapeutics, a Cambridge gene therapy company focused on developing treatments for rare diseases such as hemophilia.

Dimension has completed an undisclosed Series A financing that was led by Fidelity Biosciences.

Continue reading below

Dimension also has entered into a collaboration with REGENX, gaining preferred access to NAV vector technology and rights in REGENX product programs.

“Gene therapy is a fundamental method of disease intervention, changing a patient’s genetic code to treat genetic disease, and in some cases providing a potential lifelong benefit following a single treatment,” said Dr. Thomas R. Beck, executive partner at Fidelity Biosciences and the interim chief executive of Dimension Therapeutics.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com